EMPACT-MI Kidney: SGLT2 Initiation Can Preserve Kidney Function in Post-MI Population

Published Date: 05 Sep 2024

EMPACT-MI Kidney: SGLT2 Initiation Can Preserve Kidney Function in Post-MI Population

Read Full News

Latest News

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD
HTTP error: 503

First New Drug Approved for Idiopathic Nephrotic Syndrome in 70 Years

— Anti-CD20 agent obinutuzumab (Gazyva) gets green light for patients as young as 2 years
HTTP error: 503HTTP error: 503HTTP error: 503

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

— Anti-CD20 agent obinutuzumab (Gazyva) gets green light for patients as young as 2 years
HTTP error: 503HTTP error: 503HTTP error: 503

News All Time

For Incarcerated Patients, Kidney Care Can't Wait, With Laura Maursetter, MD Laura Maursetter, MD

A nephrologist outlines gaps in CKD tracking, medication access, and transplant standards across the carceral health system.

Pacibekitug Sustains Inflammatory Biomarker Reduction in CKD in TRANQUILITY Trial Abigail Brooks, MA

The phase 2 TRANQUILITY trial found the IL-6 antibody pacibekitug produced sustained, dose-dependent reductions in hs-CRP in patients with chronic kidney disease.

New ESC, ERA Guideline Calls for Universal CKD Screening in Cardiovascular Disease Abigail Brooks, MA

The ESC and ERA issued their first joint guideline recommending universal CKD screening and expanded use of risk-modifying therapies in patients with cardiovascular disease.

Diagnosis to Data: What Patient Experience Adds to IgAN Research Bryon Wade

A principal healthcare consultant and study co-author shares his own decade-long path to an IgA nephropathy diagnosis and transplant.
HTTP error: 503HTTP error: 503

Kidney Organoids May Speed AKI Drug Screening, With Alexander Combes, PhD Alexander Combes, PhD

Alexander Combes, PhD, discusses how kidney organoids could be used to screen and repurpose drugs for acute kidney injury.

Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD Abigail Brooks, MA

Boehringer Ingelheim halted EASi-KIDNEY after a DMC found data did not support a meaningful clinical benefit on the trial's primary endpoint.

How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care George Vasquez-Rios, MD

George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
HTTP error: 503HTTP error: 503HTTP error: 503

FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome

FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome
HTTP error: 503HTTP error: 503

Kidney Transplant Disparities Persist With Intellectual, Developmental Disability

— Study suggests little impact from states' anti-discrimination laws

Recommended News For You

In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".

Immunotherapy Remains Little Used in Head and Neck Cancer

In cancer patients taking immune checkpoint inhibitors, systematic vitamin D supplementation improves outcomes.

New Gene Therapy Nears EU Nod for Bladder Cancer

An Examine More Into the Acceptance of CRISPR/Cas9 Gene Therapy for Sickle Cell Illness.

Radiotherapy after mastectomy can be avoided, study finds

Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.

Recommended Articles For You

Unlocking the Secrets of Improved Ovarian Cancer Survival Rates 

Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers 

An Overview Of Daunorubicin: What Is It Used For And How Does It Work? 

Magnetically Controlled Surgical Microdevices for Targeted Hematologic Tissue Intervention 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In 18 States, alcohol exclusion laws are still in effect.

2.

Mammo Responsibility Increases Screening; Opioids for Pain Related to Cancer? Ignored CRC Signs.

3.

Early-life exposure to air and light pollution linked to increased risk of pediatric thyroid cancer

4.

Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients

5.

Cancer Warnings on Alcohol? Surge in GI Illnesses; Swab Detects Kids' Asthma Type

1.

Exploring the Causes and Treatments of Bacterial Keratitis: A Comprehensive Guide

2.

Risk Assessment of Cancer-Associated Thrombotic Events

3.

Preventing Developmental Iron Depletion in Childhood

4.

Risk Assessment of Cancer-Associated Endocrine Disorders

5.

Uncovering the Hidden Gallons: How Much Blood Is Inside the Human Body?

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

2.

Current Scenario of Cancer- Palliative Care to Close the Care Gap

3.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

4.

L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients

5.

Understanding Blood Clotting Disorders

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot